Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK
Authors
Kuhnl, A.Roddie, C.
Kirkwood, A. A.
Chaganti, S.
Norman, J.
Lugthart, S.
Osborne, W.
Gibb, Adam
Gonzalez Arias, C.
Latif, A.
Uttenthal, B.
Seymour, F.
Jones, C.
Springell, D.
Brady, J. L.
Illidge, Timothy
Stevens, A.
Alexander, E.
Hawley, L.
O'Rourke, N.
Bedi, C.
Prestwich, R.
Frew, J.
Burns, D.
O'Reilly, M.
Sanderson, R.
Sivabalasingham, S.
Mikhaeel, N. G.
Affiliation
Department of Medical Oncology, The Christie Hospital, Manchester, UK. Cancer Sciences, University of Manchester Christie NHS Trust, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT). Of 169 patients, 65.7% had advanced stage, 36.9% bulky disease, 86.5% elevated LDH, 41.7% international prognostic index (IPI) ≥3 and 15.2% double/triple hit at the time of approval. Use of RT bridging varied from 11% to 32% between centres and increased over time. Vein-to-vein time and infusion rate did not differ between bridging modalities. RT-bridged patients had favourable outcomes with 1-year progression-free survival (PFS) of 56% for single modality and 47% for CMT (1-year PFS 43% for systemic bridging). This is the largest cohort of LBCL patients receiving RT bridging prior to CAR T reported to date. Our results show that RT bridging can be safely and effectively used even in advanced stage and high-risk disease, with low dropout rates and excellent outcomes.Citation
Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, et al. Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. British journal of haematology. 2024 Apr 9. PubMed PMID: 38594876. Epub 2024/04/10. eng.Journal
British Journal of HaematologyDOI
10.1111/bjh.19453PubMed ID
38594876Additional Links
https://dx.doi.org/10.1111/bjh.19453Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.19453
Scopus Count
Collections
Related articles
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
- Authors: Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ
- Issue date: 2020 Jul 14
- Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.
- Authors: Bailén R, Iacoboni G, Delgado J, López-Corral L, Hernani-Morales R, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Guerra-Domínguez ML, Sánchez-Pina JM, Peña M, Torrent A, Pérez-Martínez A, Bastos-Oreiro M, Reguera-Ortega JL, Martín A, Hernandez-Boluda JC, Martínez-Cibrián N, Sanz J, Briones J, Henriquez HL, Calbacho M, Mussetti A, Sancho JM, Barba P, Kwon M, GETH-TC (Spanish Group of Stem Cell Transplantation and Cell Therapy) and GELTAMO (Spanish Group of Lymphoma and Autologous Stem Cell Transplantation)
- Issue date: 2024 Oct
- Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
- Authors: Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, Lazaryan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim S, Locke FL, Robinson TJ
- Issue date: 2019 Dec 1
- Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
- Authors: Sýkorová A, Folber F, Polgárová K, Móciková H, Ďuraš J, Steinerová K, Obr A, Heindorfer A, Ladická M, Lukáčová Ľ, Čellárová E, Plameňová I, Belada D, Janíková A, Trněný M, Jančárková T, Procházka V, Vranovský A, Králiková M, Vydra J, Smolej L, Drgoňa Ľ, Sedmina M, Čermáková E, Pytlík R
- Issue date: 2024 Sep
- Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
- Authors: Eigendorff F, Filimonova I, Scholl S, Sayer-Klink A, Rummler S, Kunert C, Pietschmann K, Wittig A, Hochhaus A, Schnetzke U
- Issue date: 2024 May 1